TABLE 1.
Variables | Patient N = 335 | Univariate analysis | Multivariate analysis | |||||
HR | 95% CI | P | HR | 95% CI | P | |||
Age | ≤65 | 152 | Reference | Reference | ||||
>65 | 183 | 1.815 | 1.010–3.261 | 0.046 | 1.944 | 1.074–3.518 | 0.028 | |
Gender | Male | 162 | Reference | |||||
Female | 173 | 1.013 | 0.775–1.324 | 0.924 | ||||
Tumor location | Right | 147 | Reference | |||||
Left | 188 | 0.967 | 0.566–1.652 | 0.903 | ||||
Tumor recurrence | No | 261 | Reference | |||||
Yes | 74 | 0.740 | 0.348–1.572 | 0.434 | ||||
Neoplasm cancer | Tumor free | 153 | Reference | |||||
With tumor | 182 | 0.924 | 0.541–1.578 | 0.771 | ||||
Residual tumor | R0 | 280 | Reference | |||||
R1 + R2 | 55 | 2.948 | 1.693- 5.133 | <0.001 | ||||
Tumor stage | I | 58 | Reference | |||||
II | 125 | 1.209 | 0.331–4.410 | 0.774 | ||||
III | 102 | 3.149 | 0.932–10.647 | 0.065 | ||||
IV | 50 | 7.806 | 2.325–26.207 | 0.001 | ||||
T stage | T1 | 12 | Reference | |||||
T2 | 57 | 0.644 | 0.067–6.192 | 0.703 | ||||
T3 | 233 | 1.827 | 0.250–13.320 | 0.522 | ||||
T4 | 33 | 4.379 | 0.554–37.600 | 0.161 | ||||
N stage | N0 | 188 | Reference | Reference | ||||
N1 | 88 | 2.498 | 1.259–4.958 | 0.009 | 2.771 | 1.331–5.766 | 0.006 | |
N2 | 59 | 4.923 | 2.522–9.609 | <0.001 | 4.116 | 1.960–8.643 | <0.001 | |
M stage | M0 | 285 | Reference | Reference | ||||
M1 | 50 | 4.178 | 2.413–7.234 | <0.001 | 3.280 | 1.791–6.005 | <0.001 | |
lncRNA risk | Low | 168 | Reference | Reference | ||||
High | 167 | 4.004 | 2.100–7.633 | <0.001 | 4.900 | 2.485–9.662 | <0.001 | |
miRNA risk | Low | 168 | Reference | Reference | ||||
High | 167 | 1.853 | 1.370–2.506 | <0.001 | 4.027 | 2.155–7.524 | <0.001 | |
mRNA risk | Low | 168 | Reference | |||||
High | 167 | 1.670 | 1.239–2.251 | 0.001 |
HR, hazard ratio; CI, confidence interval.